NEW YORK (GenomeWeb) – Meridian Bioscience today initiated revenue and earnings guidance for its fiscal 2016 and said that revenues and earnings for fiscal 2015 are expected to be at the low end of its previously stated guidance range. 

The firm said that for fiscal 2016, which starts on Oct. 1, it expects net revenues to grow between 3 percent and 5 percent on a constant currency basis, translating to a revenue range of $195 million to $200 million. EPS is expected to be in the range of $.86 to $.90. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.

Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.

Sponsored by

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms. 

Sponsored by
Canon BioMedical

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.